Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial

IMPORTANCE: Clinical evidence supports effectiveness of cannabidiol for treatment-resistant seizures in Dravet syndrome, but this trial is the first to evaluate the 10-mg/kg/d dose. OBJECTIVE: To evaluate the efficacy and safety of a pharmaceutical formulation of cannabidiol, 10 and 20 mg/kg/d, vs p...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Ian, Scheffer, Ingrid E., Gunning, Boudewijn, Sanchez-Carpintero, Rocio, Gil-Nagel, Antonio, Perry, M. Scott, Saneto, Russell P., Checketts, Daniel, Dunayevich, Eduardo, Knappertz, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052786/
https://www.ncbi.nlm.nih.gov/pubmed/32119035
http://dx.doi.org/10.1001/jamaneurol.2020.0073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052786/
https://www.ncbi.nlm.nih.gov/pubmed/32119035
http://dx.doi.org/10.1001/jamaneurol.2020.0073

Ejemplares similares